Prevalence, patient characteristics, and outcomes of high-dose upadacitinib in inflammatory bowel disease
Therapeutic Advances in Gastroenterology
Published online on May 21, 2026
Abstract
Therapeutic Advances in Gastroenterology, Volume 19, January-December 2026.
Background:Off-label high-dose upadacitinib (UPA) may be necessary for select inflammatory bowel disease (IBD) patients.Objectives:To evaluate the rates, patient characteristics, and outcomes of extended induction and high-dose UPA maintenance in IBD....
Background:Off-label high-dose upadacitinib (UPA) may be necessary for select inflammatory bowel disease (IBD) patients.Objectives:To evaluate the rates, patient characteristics, and outcomes of extended induction and high-dose UPA maintenance in IBD....